Can lactoferrin prevent neonatal sepsis and necrotizing enterocolitis?

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 5, 2009, Pages 515-525

  Venkatesh, Mohan ^a   Abrams, Steven ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CHILDREN S NUTRITION RESEARCH CENTER   (United States)

Author keywords

Broad spectrum antimicrobial activity; Immunity; Inflammation; Lactoferrin; Necrotizing enterocolitis; Neonate; Sepsis

Indexed keywords

AMOXICILLIN; AMPHOTERICIN B; ANTIBIOTIC AGENT; CLARITHROMYCIN; FLUCONAZOLE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; LACTOFERRIN; LYSOZYME; MINOCYCLINE; NAFCILLIN; PROBIOTIC AGENT; PYRIMETHAMINE; RIBAVIRIN; TETRACYCLINE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN; ANTIINFECTIVE AGENT; IMMUNOLOGIC FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; BACTERICIDAL ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GASTRITIS; HUMAN; IMMUNOMODULATION; INFECTION PREVENTION; INFLAMMATION; INTESTINE CELL; LACTOBACILLUS RHAMNOSUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NECROTIZING ENTEROCOLITIS; NEWBORN MORBIDITY; NEWBORN MORTALITY; NEWBORN SEPSIS; NONHUMAN; OPTIMAL DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; NEWBORN; PATHOPHYSIOLOGY; PREMATURITY; SEPSIS;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISEASE MODELS, ANIMAL; ENTEROCOLITIS, NECROTIZING; HUMANS; IMMUNOLOGIC FACTORS; INFANT, NEWBORN; INFANT, PREMATURE; INFLAMMATION; LACTOFERRIN; SEPSIS;

EID: 68249158646     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.25     Document Type: Review

References (143)

1. Lin PW, Stoll BJ. Necrotising enterocolitis. Lancet 368(9543), 1271-1283 (2006). •• Comprehensive review on necrotizing enterocolitis.
2. Stoll BJ, Hansen N, Fanaroff AA et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 110(2 Pt 1), 285-291 (2002). (Pubitemid 34833012)
3. Stoll BJ, Hansen NI, Higgins RD et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of Gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr. Infect. Dis. J. 24(7), 635-639 (2005).
4. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century - a clinical super-challenge. N. Engl. J. Med. 360(5), 439-443 (2009). • Editorial on the current resistance of bacteria.
5. Speer CP. Inflammatory mechanisms in neonatal chronic lung disease. Eur. J. Pediatr. 158(Suppl. 1), S18-S22 (1999).
6. Adams-Chapman I, Stoll BJ. Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Curr. Opin. Infect. Dis. 19(3), 290-297 (2006). (Pubitemid 43740369)
7. Lawn JE, Wilczynska-Ketende K, Cousens SN. Estimating the causes of 4 million neonatal deaths in the year 2000. Int. J. Epidemiol. 35(3), 706-718 (2006).
8. Stoll BJ, Hansen NI, Adams-Chapman I et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 292(19), 2357-2365 (2004). (Pubitemid 39491920)
9. Fanaroff AA, Stoll BJ, Wright LL et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am. J. Obstet. Gynecol. 196(2), 147 e141-e148 (2007). •• Current trends of neonatal mortality and morbidity.
10. Lemons JA, Bauer CR, Oh W et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 107(1), E1 (2001).
11. Caplan MS, Hsueh W. Necrotizing enterocolitis: role of platelet activating factor, endotoxin, and tumor necrosis factor. J. Pediatr. 117(1 Pt 2), S47-S51 (1990). (Pubitemid 20201711)
12. Caplan MS, Sun XM, Hseuh W, Hageman JR. Role of platelet activating factor and tumor necrosis factor-α in neonatal necrotizing enterocolitis. J. Pediatr. 116(6), 960-964 (1990).
13. Stoll BJ, Hansen NI, Adams-Chapman I et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 292(19), 2357-2365 (2004). (Pubitemid 39491920)
14. Blackwell TS, Christman JW. The role of nuclear factor-κB in cytokine gene regulation. Am. J. Respir. Cell. Mol. Biol. 17(1), 3-9 (1997).
15. Neish AS. Molecular aspects of intestinal epithelial cell-bacterial interactions that determine the development of intestinal inflammation. Inflamm. Bowel Dis. 10(2), 159-168 (2004).
16. Edelson MB, Bagwell CE, Rozycki HJ. Circulating pro- and counterinflammatory cytokine levels and severity in necrotizing enterocolitis. Pediatrics 103(4 Pt 1), 766-771 (1999).
17. Ng PC, Li K, Wong RP et al. Proinflammatory and anti-inflammatory cytokine responses in preterm infants with systemic infections. Arch. Dis. Child. Fetal Neonatal. Ed. 88(3), F209-F213 (2003). (Pubitemid 36560569)
18. Harris MC, D'Angio CT, Gallagher PR, Kaufman D, Evans J, Kilpatrick L. Cytokine elaboration in critically ill infants with bacterial sepsis, necrotizing entercolitis, or sepsis syndrome: correlation with clinical parameters of inflammation and mortality. J. Pediatr. 147(4), 462-468 (2005). (Pubitemid 41446539)
19. Ward PP, Paz E, Conneely OM. Multifunctional roles of lactoferrin: a critical overview. Cell. Mol. Life Sci. 62(22), 2540-2548 (2005). (Pubitemid 41721229)
20. Moguilevsky N, Retegui LA, Masson PL. Comparison of human lactoferrins from milk and neutrophilic leucocytes. Relative molecular mass, isoelectric point, iron-binding properties and uptake by the liver. Biochem. J. 229(2), 353-359 (1985). (Pubitemid 15232043)
21. Sanchez L, Calvo M, Brock JH. Biological role of lactoferrin. Arch. Dis. Child. 67(5), 657-661 (1992).
22. Baker EN, Anderson BF, Baker HM et al. Three-dimensional structure of lactoferrin. Implications for function, including comparisons with transferrin. Adv. Exp. Med. Biol. 443, 1-14 (1998).
23. Hennart PF, Brasseur DJ, Delogne-Desnoeck JB, Dramaix MM, Robyn CE. Lysozyme, lactoferrin, and secretory immunoglobulin A content in breast milk: influence of duration of lactation, nutrition status, prolactin status, and parity of mother. Am. J. Clin. Nutr. 53(1), 32-39 (1991).
24. Masson PL, Heremans JF. Lactoferrin in milk from different species. Comp. Biochem. Physiol. B. 39(1), 119-129 (1971).
25. Masson P, Heremans J, Dive C. An iron-binding protein common to many external secretions. Clinica Chimica Acta 14, 735-739 (1966).
26. Masson P, Heremans JF, Schonne E. Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J. Exp. Med. 130, 643-658 (1969).
27. Bennett RM, Kokocinski T. Lactoferrin content of peripheral blood cells. Br. J. Haematol. 39(4), 509-521 (1978). (Pubitemid 8398734)
28. Kalmar JR, Arnold RR. Killing of Actinobacillus actinomycetemcomitans by human lactoferrin. Infect. Immun. 56(10), 2552-2557 (1988).
29. Yamauchi K, Tomita M, Giehl TJ, Ellison RT 3rd. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect. Immun. 61(2), 719-728 (1993). (Pubitemid 23030865)
30. Farnaud S, Evans RW. Lactoferrin - a multifunctional protein with antimicrobial properties. Mol. Immunol. 40(7), 395-405 (2003). (Pubitemid 37244032)
31. Orsi N. The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 17(3), 189-196 (2004). (Pubitemid 38987136)
32. van der Kraan MI, van Marle J, Nazmi K et al. Ultrastructural effects of antimicrobial peptides from bovine lactoferrin on the membranes of Candida albicans and Escherichia coli. Peptides 26(9), 1537-1542 (2005). (Pubitemid 41169745)
33. Arnold RR, Russell JE, Champion WJ, Gauthier JJ. Bactericidal activity of human lactoferrin: influence of physical conditions and metabolic state of the target microorganism. Infect. Immun. 32(2), 655-660 (1981).
34. Bortner CA, Arnold RR, Miller RD. Bactericidal effect of lactoferrin on Legionella pneumophila: effect of the physiological state of the organism. Can. J. Microbiol. 35(11), 1048-1051 (1989).
35. Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell. Mol. Life Sci. 62(22), 2588-2598 (2005).
36. Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J. Appl. Bacteriol. 73(6), 472-479 (1992). (Pubitemid 23160081)
37. Vorland LH, Ulvatne H, Andersen J et al. Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand J. Infect. Dis. 30(5), 513-517 (1998). (Pubitemid 29054360)
38. Lupetti A, Paulusma-Annema A, Welling MM, Senesi S, van Dissel JT, Nibbering PH. Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob. Agents Chemother. 44(12), 3257-3263 (2000). (Pubitemid 33009481)
39. Nibbering PH, Ravensbergen E, Welling MM et al. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect. Immun. 69(3), 1469-1476 (2001). • Evidence of the efficacy of lactoferrin (Lf) against resistant bacteria. (Pubitemid 32187596)
40. Valenti P, Antonini G. Lactoferrin: an important host defence against microbial and viral attack. Cell. Mol. Life Sci. 62(22), 2576-2587 (2005). •• Comprehensive review on the antimicrobial effects of Lf. (Pubitemid 41721231)
41. Suzuki YA, Lopez V, Lonnerdal B. Mammalian lactoferrin receptors: structure and function. Cell. Mol. Life Sci. 62(22), 2560-2575 (2005). • Review on human Lf receptors. (Pubitemid 41721230)
42. Curran CS, Demick KP, Mansfield JM. Lactoferrin activates macrophages via TLR4-dependent and -independent signaling pathways. Cell. Immunol. 242(1), 23-30 (2006).
43. Legrand D, Elass E, Carpentier M, Mazurier J. Lactoferrin: a modulator of immune and inflammatory responses. Cell. Mol. Life Sci. 62(22), 2549-2559 (2005). •• Comprehensive review on the immunoregulatory effects of Lf. (Pubitemid 41722207)
44. Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA, Mattsby-Baltzer I. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-κB. Cell. Immunol. 220(2), 83-95 (2002). • Mechanism of the anti-inflammatory effect of Lf. (Pubitemid 36349060)
45. Kruzel ML, Harari Y, Mailman D, Actor JK, Zimecki M. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin. Exp. Immunol. 130(1), 25-31 (2002).
46. Legrand D, Elass E, Carpentier M, Mazurier J. Interactions of lactoferrin with cells involved in immune function. Biochem. Cell Biol. 84(3), 282-290 (2006). (Pubitemid 44341302)
47. Guillen C, McInnes IB, Vaughan DM et al. Enhanced Th1 response to Staphylococcus aureus infection in human lactoferrin-transgenic mice. J. Immunol. 168(8), 3950-3957 (2002). (Pubitemid 34298399)
48. Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br. J. Exp. Pathol. 70(6), 697-704 (1989). (Pubitemid 20022137)
49. Edde L, Hipolito RB, Hwang FF, Headon DR, Shalwitz RA, Sherman MP. Lactoferrin protects neonatal rats from gut-related systemic infection. Am. J. Physiol. Gastrointest. Liver Physiol. 281(5), G1140-G1150 (2001). (Pubitemid 33121704)
50. Artym J, Zimecki M, Kruzel ML. Enhanced clearance of Escherichia coli and Staphylococcus aureus in mice treated with cyclophosphamide and lactoferrin. Int. Immunopharmacol. 4(9), 1149-1157 (2004). (Pubitemid 38900852)
51. Venkatesh M, Pham D, Kong L, Weisman L. Prophylaxis with lactoferrin, a novel antimicrobial agent, enhances survival in a neonatal rat model of co-infection. Adv. Ther. 24(5), 941-954 (2007). (Pubitemid 350274771)
52. Kuwata H, Yamauchi K, Teraguchi S et al. Functional fragments of ingested lactoferrin are resistant to proteolytic degradation in the gastrointestinal tract of adult rats. J. Nutr. 131(8), 2121-2127 (2001). (Pubitemid 32720641)
53. Hutchens TW, Henry JF, Yip TT et al. Origin of intact lactoferrin and its DNA-binding fragments found in the urine of human milk-fed preterm infants. Evaluation by stable isotopic enrichment. Pediatr. Res. 29(3), 243-250 (1991).
54. Togawa J, Nagase H, Tanaka K et al. Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J. Gastroenterol. Hepatol. 17(12), 1291-1298 (2002). (Pubitemid 34666177)
55. Fischer R, Debbabi H, Blais A et al. Uptake of ingested bovine lactoferrin and its accumulation in adult mouse tissues. Int. Immunopharmacol. 7(10), 1387-1393 (2007). (Pubitemid 47161068)
56. Takeuchi T, Jyonotsuka T, Kamemori N et al. Enteric-formulated lactoferrin was more effectively transported into blood circulation from gastrointestinal tract in adult rats. Exp. Physiol. 91(6), 1033-1040 (2006). (Pubitemid 44690815)
57. Dial EJ, Lichtenberger LM. Effect of lactoferrin on Helicobacter felis induced gastritis. Biochem. Cell Biol. 80(1), 113-117 (2002).
58. Togawa J, Nagase H, Tanaka K et al. Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am. J. Physiol. Gastrointest. Liver Physiol. 283(1), G187-G195 (2002). (Pubitemid 34666177)
59. Gomez HF, Ochoa TJ, Herrera-Insua I, Carlin LG, Cleary TG. Lactoferrin protects rabbits from Shigella flexneri-induced inflammatory enteritis. Infect. Immun. 70(12), 7050-7053 (2002). (Pubitemid 35387941)
60. Yajima M, Yajima T, Kuwata T. Intraperitoneal injection of lactoferrin ameliorates severe albumin extravasation and neutrophilia in LPS-induced inflammation in neonatal rats. Biomed. Res. 26(6), 249-255 (2005). (Pubitemid 43137332)
61. Kruzel ML, Harari Y, Chen CY, Castro GA. Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice. Inflammation 24(1), 33-44 (2000). (Pubitemid 30105938)
62. Hirotani Y, Ikeda K, Kato R et al. Protective effects of lactoferrin against intestinal mucosal damage induced by lipopolysaccharide in human intestinal Caco-2 cells. Yakugaku Zasshi 128(9), 1363-1368 (2008).
63. Reiter B. The biological significance of the non-immunoglobulin protective proteins in milk: lysozyme, lactoferrin, lactoperoxidase. Devel. Dairy Chem. 3, 281-336 (1985).
64. Buccigrossi V, de Marco G, Bruzzese E et al. Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. Pediatr. Res. 61(4), 410-414 (2007). (Pubitemid 46569292)
65. Trumpler U, Straub PW, Rosenmund A. Antibacterial prophylaxis with lactoferrin in neutropenic patients. Eur. J. Clin. Microbiol. Infect. Dis. 8(4), 310-313 (1989). (Pubitemid 19111515)
66. Tomita M, Wakabayashi H, Yamauchi K, Teraguchi S, Hayasawa H. Bovine lactoferrin and lactoferricin derived from milk: production and applications. Biochem. Cell Biol. 80(1), 109-112 (2002). (Pubitemid 34194235)
67. King JC Jr, Cummings GE, Guo N et al. A double-blind, placebo-controlled, pilot study of bovine lactoferrin supplementation in bottle-fed infants. J. Pediatr. Gastroenterol. Nutr. 44(2), 245-251 (2007). (Pubitemid 46175080)
68. Cerven D, DeGeorge G, Bethell D. 28-day repeated dose oral toxicity of recombinant human apo-lactoferrin or recombinant human lysozyme in rats. Regul. Toxicol. Pharmacol. 51(2), 162-167 (2008).
69. Manzoni P, Stolfi I, Bollani L et al. A Multicenter, randomized trial on prophylactic bovine lactoferrin in preterm neonates for prevention of late-onset sepsis. Presented at: The 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) & 46th Annual Meeting of the Infectious Diseases Society of America (IDSA). Washington DC, USA, 25-28 October 2008.
70. Zavaleta N, Figueroa D, Rivera J, Sanchez J, Alfaro S, Lonnerdal B. Efficacy of rice-based oral rehydration solution containing recombinant human lactoferrin and lysozyme in Peruvian children with acute diarrhea. J. Pediatr. Gastroenterol. Nutr. 44(2), 258-264 (2007). (Pubitemid 46188074)
71. Venkatesh M, Liang R. Human recombinant lactoferrin is synergistic with antimicrobials commonly used in neonatal practice against coagulase negative staphylococci and C. albicans causing neonatal sepsis. J. Med. Microbiol. (2008) (In Press).
72. Sherman MP, Bennett SH, Hwang FF, Yu C. Neonatal small bowel epithelia: enhancing anti-bacterial defense with lactoferrin and Lactobacillus GG. Biometals 17(3), 285-289 (2004). (Pubitemid 38987151)
73. Leitch EC, Willcox MD. Elucidation of the antistaphylococcal action of lactoferrin and lysozyme. J. Med. Microbiol. 48(9), 867-871 (1999).
74. Leitch EC, Willcox MD. Lactoferrin increases the susceptibility of S. epidermidis biofilms to lysozyme and vancomycin. Curr. Eye Res. 19(1), 12-19 (1999).
75. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature 417(6888), 552-555 (2002). • Antibiofilm activity of Lf.
76. Williams TJ, Schneider RP, Willcox MD. The effect of protein-coated contact lenses on the adhesion and viability of Gram negative bacteria. Curr. Eye Res. 27(4), 227-235 (2003).
77. Berlutti F, Ajello M, Bosso P et al. Both lactoferrin and iron influence aggregation and biofilm formation in Streptococcus mutans. Biometals 17(3), 271-278 (2004). (Pubitemid 38987149)
78. Aguilera O, Andres MT, Heath J, Fierro JF, Douglas CW. Evaluation of the antimicrobial effect of lactoferrin on Porphyromonas gingivalis, Prevotella intermedia and Prevotella nigrescens. FEMS Immunol. Med. Microbiol. 21(1), 29-36 (1998). (Pubitemid 28258965)
79. Visca P, Berlutti F, Vittorioso P, Dalmastri C, Thaller MC, Valenti P. Growth and adsorption of Streptococcus mutans 6715-13 to hydroxyapatite in the presence of lactoferrin. Med. Microbiol. Immunol. 178(2), 69-79 (1989). (Pubitemid 19072437)
80. Schaible UE, Collins HL, Priem F, Kaufmann SH. Correction of the iron overload defect in β-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. J. Exp. Med. 196(11), 1507-1513 (2002). (Pubitemid 35424944)
81. Kuipers ME, de Vries HG, Eikelboom MC, Meijer DK, Swart PJ. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob. Agents Chemother. 43(11), 2635-2641 (1999).
82. Viejo-Diaz M, Andres MT, Fierro JF. Modulation of in vitro fungicidal activity of human lactoferrin against Candida albicans by extracellular cation concentration and target cell metabolic activity. Antimicrob. Agents Chemother. 48(4), 1242-1248 (2004). (Pubitemid 38405478)
83. Lupetti A, Danesi R, van 't Wout JW, van Dissel JT, Senesi S, Nibbering PH. Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. Expert Opin. Investig. Drugs 11(2), 309-318 (2002).
84. Lupetti A, Paulusma-Annema A, Welling MM et al. Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrob. Agents Chemother. 47(1), 262-267 (2003). (Pubitemid 36070373)
85. Wakabayashi H, Abe S, Okutomi T, Tansho S, Kawase K, Yamaguchi H. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol. Immunol. 40(11), 821-825 (1996). (Pubitemid 27034132)
86. Wakabayashi H, Okutomi T, Abe S, Hayasawa H, Tomita M, Yamaguchi H. Enhanced anti-Candida activity of neutrophils and azole antifungal agents in the presence of lactoferrin-related compounds. Adv. Exp. Med. Biol. 443, 229-237 (1998). (Pubitemid 28432190)
87. Wakabayashi H, Takase M, Tomita M. Lactoferricin derived from milk protein lactoferrin. Curr. Pharm. Des. 9(16), 1277-1287 (2003). (Pubitemid 36592136)
88. Hasegawa K, Motsuchi W, Tanaka S, Dosako S. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn J. Med. Sci. Biol. 47(2), 73-85 (1994). (Pubitemid 24333771)
89. Marchetti M, Longhi C, Conte MP, Pisani S, Valenti P, Seganti L. Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. Antiviral Res. 29(2-3), 221-231 (1996). (Pubitemid 26135179)
90. Marchetti M, Pisani S, Antonini G, Valenti P, Seganti L, Orsi N. Metal complexes of bovine lactoferrin inhibit in vitro replication of herpes simplex virus type 1 and 2. Biometals 11(2), 89-94 (1998). (Pubitemid 28140327)
91. Jenssen H, Sandvik K, Andersen JH, Hancock RE, Gutteberg TJ. Inhibition of HSV cell-to-cell spread by lactoferrin and lactoferricin. Antiviral Res. 79(3), 192-198 (2008).
92. Ammendolia MG, Marchetti M, Superti F. Bovine lactoferrin prevents the entry and intercellular spread of herpes simplex virus type 1 in green monkey kidney cells. Antiviral Res. 76(3), 252-262 (2007). (Pubitemid 47600359)
93. Beljaars L, Bakker HI, van der Strate BW et al. The antiviral protein human lactoferrin is distributed in the body to cytomegalovirus (CMV) infection-prone cells and tissues. Pharm. Res. 19(1), 54-62 (2002). (Pubitemid 34075107)
94. Beljaars L, van der Strate BW, Bakker HI et al. Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. Antiviral Res. 63(3), 197-208 (2004). (Pubitemid 39286757)
95. Harmsen MC, Swart PJ, de Bethune MP et al. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J. Infect. Dis. 172(2), 380-388 (1995).
96. Puddu P, Borghi P, Gessani S, Valenti P, Belardelli F, Seganti L. Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection. Int. J. Biochem. Cell Biol. 30(9), 1055-1062 (1998). (Pubitemid 28484861)
97. Berkhout B, Floris R, Recio I, Visser S. The antiviral activity of the milk protein lactoferrin against the human immunodeficiency virus type 1. Biometals 17(3), 291-294 (2004). (Pubitemid 38987152)
98. Hara K, Ikeda M, Saito S et al. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol. Res. 24(3), 228 (2002). (Pubitemid 35314579)
99. Tanaka K, Ikeda M, Nozaki A et al. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Jpn J. Cancer Res. 90(4), 367-371 (1999). (Pubitemid 29213539)
100. Iwasa M, Kaito M, Ikoma J et al. Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. Am. J. Gastroenterol. 97(3), 766-767 (2002). (Pubitemid 34245920)
101. Ikeda M, Nozaki A, Sugiyama K et al. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res. 66(1), 51-63 (2000). (Pubitemid 30069804)
102. Yi M, Kaneko S, Yu DY, Murakami S. Hepatitis C virus envelope proteins bind lactoferrin. J. Virol. 71(8), 5997-6002 (1997). (Pubitemid 27304937)
103. Kaito M, Iwasa M, Fujita N et al. Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin. J. Gastroenterol. Hepatol. 22(11), 1894-1897 (2007).
104. Sano H, Nagai K, Tsutsumi H, Kuroki Y. Lactoferrin and surfactant protein A exhibit distinct binding specificity to F protein and differently modulate respiratory syncytial virus infection. Eur. J. Immunol. 33(10), 2894-2902 (2003). (Pubitemid 37337155)
105. Superti F, Ammendolia MG, Valenti P, Seganti L. Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med. Microbiol. Immunol. 186(2-3), 83-91 (1997). (Pubitemid 27477875)
106. Marchetti M, Superti F, Ammendolia MG, Rossi P, Valenti P, Seganti L. Inhibition of poliovirus type 1 infection by iron-, manganese- and zinc-saturated lactoferrin. Med. Microbiol. Immunol. 187(4), 199-204 (1999). (Pubitemid 29216755)
107. Arnold D, Di Biase AM, Marchetti M et al. Antiadenovirus activity of milk proteins: lactoferrin prevents viral infection. Antiviral Res. 53(2), 153-158 (2002). (Pubitemid 34062835)
108. Lin TY, Chu C, Chiu CH. Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. J. Infect. Dis. 186(8), 1161-1164 (2002). (Pubitemid 35177120)
109. Di Biase AM, Pietrantoni A, Tinari A et al. Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity. J. Med. Virol. 69(4), 495-502 (2003). (Pubitemid 36249863)
110. Omata Y, Satake M, Maeda R et al. Reduction of the infectivity of Toxoplasma gondii and Eimeria stiedai sporozoites by treatment with bovine lactoferricin. J. Vet. Med. Sci. 63(2), 187-190 (2001). (Pubitemid 33674513)
111. Tanaka T, Omata Y, Narisawa M et al. Growth inhibitory effect of bovine lactoferrin on Toxoplasma gondii tachyzoites in murine macrophages: role of radical oxygen and inorganic nitrogen oxide in Toxoplasma growth-inhibitory activity. Vet. Parasitol. 68(1-2), 27-33 (1997). (Pubitemid 27128058)
112. Cirioni O, Giacometti A, Barchiesi F, Scalise G. Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. J. Antimicrob. Chemother. 46(4), 577-582 (2000). (Pubitemid 30793867)
113. Konishi M, Iwasa M, Yamauchi K et al. Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. Hepatol. Res. 36(1), 27-32 (2006). (Pubitemid 44309286)
114. Appelmelk BJ, An YQ, Geerts M et al. Lactoferrin is a lipid A-binding protein. Infect. Immun. 62(6), 2628-2632 (1994).
115. Elass E, Masson M, Mazurier J, Legrand D. Lactoferrin inhibits the lipopolysaccharide-induced expression and proteoglycan-binding ability of interleukin-8 in human endothelial cells. Infect. Immun. 70(4), 1860-1866 (2002).
116. Elass-Rochard E, Legrand D, Salmon V et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide- binding protein. Infect. Immun. 66(2), 486-491 (1998). (Pubitemid 28074186)
117. Brandenburg K, Jurgens G, Muller M, Fukuoka S, Koch MH. Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol. Chem. 382(8), 1215-1225 (2001). (Pubitemid 32894028)
118. Baveye S, Elass E, Mazurier J, Legrand D. Lactoferrin inhibits the binding of lipopolysaccharides to L-selectin and subsequent production of reactive oxygen species by neutrophils. FEBS Lett. 469(1), 5-8 (2000). (Pubitemid 30119858)
119. Baveye S, Elass E, Fernig DG, Blanquart C, Mazurier J, Legrand D. Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14- lipopolysaccharide complex. Infect. Immun. 68(12), 6519-6525 (2000). (Pubitemid 32463349)
120. Britigan BE, Lewis TS, Waldschmidt M, McCormick ML, Krieg AM. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. J. Immunol. 167(5), 2921-2928 (2001). (Pubitemid 32768927)
121. Sawatzki G, Rich IN. Lactoferrin stimulates colony stimulating factor production in vitro and in vivo. Blood Cells 15(2), 371-385 (1989). (Pubitemid 19147925)
122. Broxmeyer HE, Williams DE, Cooper S et al. Comparative effects in vivo of recombinant murine interleukin 3, natural murine colony-stimulating factor-1, and recombinant murine granulocyte-macrophage colony-stimulating factor on myelopoiesis in mice. J. Clin. Invest. 79(3), 721-730 (1987). (Pubitemid 17050895)
123. Machnicki M, Zimecki M, Zagulski T. Lactoferrin regulates the release of tumour necrosis factor a and interleukin 6 in vivo. Int. J. Exp. Pathol. 74(5), 433-439 (1993). (Pubitemid 23304079)
124. Kai K, Komine K, Komine Y et al. Lactoferrin stimulates A Staphylococcus aureus killing activity of bovine phagocytes in the mammary gland. Microbiol. Immunol. 46(3), 187-194 (2002). (Pubitemid 34289015)
125. Kijlstra A, Jeurissen SH. Modulation of classical C3 convertase of complement by tear lactoferrin. Immunology 47(2), 263-270 (1982). (Pubitemid 12031138)
126. Rainard P. Activation of the classical pathway of complement by binding of bovine lactoferrin to unencapsulated Streptococcus agalactiae. Immunology 79(4), 648-652 (1993). (Pubitemid 23246905)
127. Zimecki M, Artym J, Chodaczek G et al. Immunoregulatory function of lactoferrin in immunosuppressed and autoimmune animals. Postepy. Hig. Med. Dosw. (Online) 61, 283-287 (2007).
128. Zimecki M, Kocieba M, Chodaczek G, Houszka M, Kruzel ML. Lactoferrin ameliorates symptoms of experimental encephalomyelitis in Lewis rats. J. Neuroimmunol. 182(1-2), 160-166 (2007). (Pubitemid 46026715)
129. - murine thymocytes. Immunol. Lett. 30(1), 119-123 (1991).
130. Zimecki M, Mazurier J, Spik G, Kapp JA. Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology 86(1), 122-127 (1995).
131. Yamauchi K, Wakabayashi H, Hashimoto S, Teraguchi S, Hayasawa H, Tomita M. Effects of orally administered bovine lactoferrin on the immune system of healthy volunteers. Adv. Exp. Med. Biol. 443, 261-265 (1998). (Pubitemid 28432195)
132. Shimizu K, Matsuzawa H, Okada K et al. Lactoferrin-mediated protection of the host from murine cytomegalovirus infection by a T-cell-dependent augmentation of natural killer cell activity. Arch. Virol. 141(10), 1875-1889 (1996).
133. Shau H, Kim A, Golub SH. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. J. Leukoc. Biol. 51(4), 343-349 (1992).
134. Kuhara T, Yamauchi K, Tamura Y, Okamura H. Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J. Interferon Cytokine Res. 26(7), 489-499 (2006). (Pubitemid 44061089)
135. Damiens E, Mazurier J, el Yazidi I et al. Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumour cells. Biochim. Biophys. Acta 1402(3), 277-287 (1998). (Pubitemid 28206922)
136. Miyauchi H, Hashimoto S, Nakajima M, Shinoda I, Fukuwatari Y, Hayasawa H. Bovine lactoferrin stimulates the phagocytic activity of human neutrophils: identification of its active domain. Cell. Immunol. 187(1), 34-37 (1998). (Pubitemid 28359692)
137. de la Rosa G, Yang D, Tewary P, Varadhachary A, Oppenheim JJ. Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. J. Immunol. 180(10), 6868-6876 (2008).
138. Spadaro M, Caorsi C, Ceruti P et al. Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB J. 22(8), 2747-2757 (2008).
139. Wakabayashi H, Takakura N, Yamauchi K et al. Effect of lactoferrin feeding on the host antifungal response in guinea-pigs infected or immunised with Trichophyton mentagrophytes. J. Med. Microbiol. 51(10), 844-850 (2002). (Pubitemid 35222785)
140. Takakura N, Wakabayashi H, Ishibashi H et al. Effect of orally administered bovine lactoferrin on the immune response in the oral candidiasis murine model. J. Med. Microbiol. 53(Pt 6), 495-500 (2004). (Pubitemid 38803042)
141. Ishii K, Takamura N, Shinohara M et al. Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol. Res. 25(3), 226-233 (2003). (Pubitemid 36546348)
142. Zimecki M, Kocieba M, Kruzel M. Immunoregulatory activities of lactoferrin in the delayed type hypersensitivity in mice are mediated by a receptor with affinity to mannose. Immunobiology 205(1), 120-131 (2002). (Pubitemid 34285411)
143. Chodaczek G, Zimecki M, Lukasiewicz J, Lugowski C. A complex of lactoferrin with monophosphoryl lipid A is an efficient adjuvant of the humoral and cellular immune response in mice. Med. Microbiol. Immunol. 195(4), 207-216 (2006). (Pubitemid 44600381)